MarketCapExport financials
Chembio Diagnostics (CEMI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Chembio Diagnostics Income Statement 2022-2009 | CEMI
Brief overview of revenue and earnings at Chembio Diagnostics
This overview is based on financial performance over the past five years. Chembio Diagnostics reported revenue of 24 million dollars in 2017 and 49.5 million dollars by 2022. The total change was +106.2%, with a CAGR of approximately 15.6%. Top-line growth remained consistently strong over the period.
At the gross-profit level, the result moved from 1.4 million dollars to 10.9 million dollars, a change of +662.2%. Direct costs outpaced revenue, limiting the benefit of changes in sales. At the margin level, the figure shifted from 6% to 22.1%. The margin shift points to a more favorable sales-and-cost structure.
EBITDA was −$5.2 million at the beginning and −$21.1 million at the end of the period (−305%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin moved from −21.7% to −42.6%. Operating return per unit of revenue declined.
Net income moved from −6.4 million dollars at the start to −23.3 million dollars at the end. Larger losses indicate rising pressure on the business.
Over the period, capitalization shifted from $101 million to $12.6 million (−87.5%). Capitalization lags the underlying business improvement.
What the figures show
Signs of deterioration dominate the five-year picture. The positive side is supported by improving gross profitability and revenue expansion. The most visible risks are lower net income, weaker operating efficiency and a narrow EBITDA buffer. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
12.6 M | 27.7 M | 90.7 M | 77.3 M | 81.7 M | 101 M | 72.2 M | 51.3 M | 37.3 M | 30.3 M | 37.8 M | 26.5 M | - | - |
Shares |
32.3 M | 24.3 M | 19.1 M | 17 M | 14.4 M | 12.3 M | 10.6 M | 9.63 M | 9.53 M | 8.99 M | 7.99 M | 7.87 M | 62.1 M | - |
Historical Prices |
0.39 | 1.14 | 4.75 | 4.56 | 5.66 | 8.2 | 6.8 | 5.33 | 3.91 | 3.37 | 4.73 | 3.36 | - | - |
Net Income |
-23.3 M | -33.9 M | -25.5 M | -13.7 M | -7.87 M | -6.37 M | -13.3 M | -2.4 M | -1.14 M | 531 K | 941 K | 6.21 M | 2.51 M | - |
Revenue |
49.5 M | 47.8 M | 32.5 M | 34.5 M | 34.6 M | 24 M | 17.9 M | 24.3 M | 27.6 M | 29.5 M | 25.6 M | 19.4 M | - | - |
Cost of Revenue |
38.6 M | 34.5 M | 23.9 M | 22.4 M | 22.6 M | 12.9 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | 6.58 M | 12.1 M | 12 M | 1.44 M | 725 K | 1.87 M | 10.8 M | 12.3 M | 10.8 M | 9.39 M | 8.1 M | - |
Operating Income |
-23.6 M | -31.1 M | -23.1 M | -13.3 M | -7.98 M | -6.48 M | -7.57 M | -3.55 M | -1.55 M | 1 M | 1.45 M | 1.09 M | 2.57 M | - |
Interest Expense |
- | - | - | - | - | 2.94 K | - | 836 | - | 335 | 9.5 K | 18.6 K | 14.7 K | - |
EBITDA |
-21.1 M | -28.1 M | -20.4 M | -11.4 M | -7.08 M | -5.21 M | -6.43 M | -2.18 M | -811 K | 1.61 M | 1.98 M | 1.53 M | 2.86 M | - |
Operating Expenses |
- | - | 28.5 M | 24.7 M | 41.4 M | 30.5 M | 25.4 M | 27.8 M | 12.4 M | 11.3 M | 9.34 M | 8.3 M | 5.53 M | - |
General and Administrative Expenses |
24.3 M | 24.8 M | 21 M | 16.1 M | 11.1 M | 8.96 M | 7.6 M | 7.66 M | 7.53 M | 5.46 M | 4.85 M | 3.42 M | 2.94 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 32.3 M | 30.2 M | 30.1 M | 30.1 M | 26.7 M | 20.2 M | 20.2 M | 20.2 M | 20.1 M | 18.9 M | 17.2 M | 17.7 M | 16.9 M | 16.9 M | 17.2 M | 17.2 M | 14.2 M | 14.2 M | 13.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12 M | 11.1 M | 9.67 M | 9.63 M | 9.63 M | 9.63 M | 9.63 M | 9.62 M | 9.61 M | 9.61 M | 9.56 M | 9.34 M | 9.32 M | 9.32 M | 9.26 M | 8.06 M | 8.04 M | 8 M | 7.99 M | 63.5 M | 7.92 M | 63.3 M | 63.1 M | 62.3 M |
Net Income |
- | -6.7 M | -6.95 M | -8.79 M | - | -6.37 M | -9.06 M | -4.5 M | - | -5.54 M | -7.84 M | -5 M | - | -3.78 M | -3.19 M | -2.82 M | - | -2.31 M | -1.73 M | -652 K | -2 M | -585 K | -2.17 M | -1.62 M | -2.56 M | -2.14 M | -8.35 M | -304 K | -649 K | -437 K | -664 K | -647 K | - | -271 K | -146 K | -225 K | - | 717 K | -241 K | 317 K | - | -292 K | 309 K | 433 K | - | 476 K | 195 M | -142 K |
Revenue |
- | 11.2 M | 9.16 M | 18.8 M | - | 12.1 M | 6.46 M | 8.72 M | - | 10.3 M | 5.11 M | 6.86 M | - | 9.72 M | 9.59 M | 8.3 M | - | 9.38 M | 8.72 M | 7.72 M | 5.99 M | 7.59 M | 4.11 M | 6.33 M | 4.25 M | 3.75 M | 3.27 M | 6.6 M | 4.42 M | 6.89 M | 6.72 M | 6.23 M | - | 7.31 M | 7.42 M | 5.81 M | - | 9.62 M | 5.39 M | 6.68 M | - | 5.01 M | 6.08 M | 6.65 M | - | 5.92 M | 3.61 M | 3.64 M |
Cost of Revenue |
- | 9.66 M | 8.09 M | 15.2 M | - | 7.9 M | 4.04 M | 3.55 M | - | 7.47 M | 5.67 M | 4.37 M | - | 6.65 M | 6.69 M | 4.77 M | - | 6.77 M | 5.94 M | 4.43 M | - | 4.06 M | 2.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.44 M | 3.52 M | 1.91 M | 3.11 M | 725 K | 1.95 M | 1.58 M | 3.17 M | 1.87 M | 2.91 M | 3.02 M | 2.69 M | - | 2.65 M | 2.98 M | 2.27 M | - | 4.06 M | 2.28 M | 2.69 M | - | 1.73 M | 2.57 M | 3.33 M | - | 2.67 M | 2.05 B | 1.93 M |
Operating Income |
- | -5.99 M | -6.22 M | -8.05 M | - | -5.63 M | -8.34 M | -3.86 M | - | -4.91 M | -7.27 M | -4.42 M | - | -3.61 M | -3.3 M | -3.1 M | - | -2.33 M | -1.75 M | -654 K | - | -589 K | -2.18 M | -1.63 M | - | -2.14 M | -2.39 M | -468 K | - | -579 K | -898 K | -875 K | - | -262 K | -233 K | -383 K | - | 1.07 M | -380 K | 487 K | - | -485 K | 512 K | 720 K | - | 479 K | 197 M | -139 K |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.07 K | - | 3.85 K | 7.72 K | 13.4 K | - | - | 1.31 K | - | - | 749 | - | - | - | - | - | - | - | - | - | 335 | - | 2.82 K | 2.32 K | 2.44 K | - | 4.87 K | 4.03 M | 4.44 K |
EBITDA |
- | -4.12 M | -5.01 M | -7.45 M | - | -3.44 M | -6.95 M | -3.17 M | - | -2.85 M | -5.83 M | -3.68 M | - | -1.94 M | -2.55 M | -2.74 M | - | -1.67 M | -1.31 M | -431 K | - | 423 K | -1.41 M | -1.15 M | - | -1.27 M | -1.81 M | -177 K | - | 403 K | -232 K | -530 K | - | 274 K | 111 K | -210 K | - | 1.52 M | -97.4 K | 627 K | - | -80.5 K | 782 K | 850 K | - | 801 K | 414 M | -26.9 K |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.4 M | - | 11.7 M | 10.5 M | 8.37 M | - | 4.11 M | 4.09 M | 4.73 M | - | 4.1 M | 3.97 M | 3.63 M | - | 3.49 M | 3.92 M | 3.56 M | - | 2.91 M | 3.22 M | 2.66 M | - | 2.98 M | 2.66 M | 2.21 M | - | 2.21 M | 2.06 M | 2.61 M | - | 2.19 M | 1.85 B | 2.07 M |
General and Administrative Expenses |
- | 5.55 M | 5.25 M | 6.95 M | - | 5.95 M | 6 M | 6.09 M | - | 5.35 M | 4.4 M | 4.16 M | - | 4.46 M | 4.1 M | 4.01 M | - | 3.03 M | 2.55 M | 2.41 M | - | 2.31 M | 2.11 M | 2.49 M | - | 1.83 M | 1.6 M | 2 M | - | 1.92 M | 2.16 M | 1.98 M | - | 1.94 M | 1.95 M | 1.46 M | - | 1.38 M | 1.16 M | 1.16 M | - | 1.21 M | 1.08 M | 1.23 M | - | 949 K | 688 M | 775 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Chembio Diagnostics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B |  USA |
 |
DarioHealth Corp.
DRIO
|
$ 2.37 | 15.05 % | $ 9.44 M |  Israel |
 |
Myriad Genetics
MYGN
|
$ 5.66 | -1.39 % | $ 524 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 4.78 | -1.24 % | $ 3.76 M | USA |
 |
QIAGEN N.V.
QGEN
|
$ 50.52 | -0.07 % | $ 11 B |  Niderland |
 |
NeoGenomics
NEO
|
$ 16.97 | -3.58 % | $ 2.17 B | USA |
 |
OPKO Health
OPK
|
$ 1.71 | 0.58 % | $ 1.28 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.22 | -5.93 % | $ 666 M | USA |
 |
Neogen Corporation
NEOG
|
$ 11.67 | -3.44 % | $ 2.54 B | USA |
 |
Precipio
PRPO
|
$ 23.56 | 6.13 % | $ 37.8 M | USA |
 |
Personalis
PSNL
|
$ 15.9 | -0.31 % | $ 1.42 B | USA |
 |
Sotera Health Company
SHC
|
$ 16.25 | -1.16 % | $ 4.61 B | USA |
 |
Quidel Corporation
QDEL
|
$ 11.56 | -4.43 % | $ 487 M | USA |
 |
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M |  Germany |
 |
Trinity Biotech plc
TRIB
|
$ 5.88 | 10.08 % | $ 2.11 B |  Irlanda |
 |
Global Cord Blood Corporation
CO
|
- | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | USA |
 |
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
- | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
$ 26.91 | 0.9 % | $ 602 M | USA |
 |
Twist Bioscience Corporation
TWST
|
$ 132.17 | -2.35 % | $ 7.9 B | USA |
 |
Organovo Holdings
ONVO
|
- | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
- | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
- | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B | Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M | Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |